BR112017004304B1 - uso de pteroestilbeno para prepação de composições tópicas no tratamento de perda de função de barreira na pele induzidas por uv - Google Patents

uso de pteroestilbeno para prepação de composições tópicas no tratamento de perda de função de barreira na pele induzidas por uv Download PDF

Info

Publication number
BR112017004304B1
BR112017004304B1 BR112017004304-1A BR112017004304A BR112017004304B1 BR 112017004304 B1 BR112017004304 B1 BR 112017004304B1 BR 112017004304 A BR112017004304 A BR 112017004304A BR 112017004304 B1 BR112017004304 B1 BR 112017004304B1
Authority
BR
Brazil
Prior art keywords
skin
pteroestilbene
loss
barrier function
treatment
Prior art date
Application number
BR112017004304-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017004304A2 (pt
Inventor
Frank L. Mayskens Jr.
Ryan W. Dellinger
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of BR112017004304A2 publication Critical patent/BR112017004304A2/pt
Publication of BR112017004304B1 publication Critical patent/BR112017004304B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
BR112017004304-1A 2014-09-04 2015-09-03 uso de pteroestilbeno para prepação de composições tópicas no tratamento de perda de função de barreira na pele induzidas por uv BR112017004304B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046068P 2014-09-04 2014-09-04
US62/046,068 2014-09-04
PCT/US2015/048422 WO2016036999A1 (en) 2014-09-04 2015-09-03 Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin

Publications (2)

Publication Number Publication Date
BR112017004304A2 BR112017004304A2 (pt) 2017-12-05
BR112017004304B1 true BR112017004304B1 (pt) 2020-12-08

Family

ID=55436471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004304-1A BR112017004304B1 (pt) 2014-09-04 2015-09-03 uso de pteroestilbeno para prepação de composições tópicas no tratamento de perda de função de barreira na pele induzidas por uv

Country Status (11)

Country Link
US (1) US9980924B2 (enrdf_load_stackoverflow)
EP (1) EP3194032B1 (enrdf_load_stackoverflow)
JP (1) JP2017525738A (enrdf_load_stackoverflow)
KR (1) KR20170045343A (enrdf_load_stackoverflow)
CN (1) CN107106877A (enrdf_load_stackoverflow)
AU (1) AU2015311799A1 (enrdf_load_stackoverflow)
BR (1) BR112017004304B1 (enrdf_load_stackoverflow)
CA (1) CA2959756C (enrdf_load_stackoverflow)
MX (1) MX375612B (enrdf_load_stackoverflow)
WO (1) WO2016036999A1 (enrdf_load_stackoverflow)
ZA (1) ZA201701510B (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9980924B2 (en) 2014-09-04 2018-05-29 The Regents Of The University Of California Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
EP3501490B1 (en) * 2016-08-17 2023-08-30 Tomoike Bio Ltd. Composition for external use that includes pterostilbene glycoside
JP7061766B2 (ja) * 2017-09-20 2022-05-02 学校法人同志社 Ｄｊ－１タンパク質産生促進用組成物
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820975B1 (fr) 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
US8703161B2 (en) 2007-08-13 2014-04-22 Elc Management, Llc Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators
US20090047309A1 (en) * 2007-08-13 2009-02-19 Maes Daniel H Cosmetic methods and compositions for repairing human skin
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
EP2322159A1 (en) 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US8841350B2 (en) * 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
JP2013075851A (ja) * 2011-09-30 2013-04-25 Fujifilm Corp 皮膚外用剤
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CN103239540B (zh) 2013-04-03 2014-11-12 广东药学院 一种凉血愈伤方提取物及治疗皮肤烧伤的复方白藜芦醇凉血愈伤油制剂
US20160067193A1 (en) 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
US9980924B2 (en) 2014-09-04 2018-05-29 The Regents Of The University Of California Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin

Also Published As

Publication number Publication date
EP3194032A1 (en) 2017-07-26
CN107106877A (zh) 2017-08-29
JP2017525738A (ja) 2017-09-07
CA2959756A1 (en) 2016-03-10
BR112017004304A2 (pt) 2017-12-05
MX2017002818A (es) 2017-08-02
EP3194032A4 (en) 2018-05-23
US20160067194A1 (en) 2016-03-10
EP3194032B1 (en) 2021-06-23
US9980924B2 (en) 2018-05-29
MX375612B (es) 2025-03-06
WO2016036999A1 (en) 2016-03-10
CA2959756C (en) 2023-02-28
AU2015311799A1 (en) 2017-03-30
ZA201701510B (en) 2018-11-28
KR20170045343A (ko) 2017-04-26

Similar Documents

Publication Publication Date Title
Yerra et al. Isoliquiritigenin reduces oxidative damage and alleviates mitochondrial impairment by SIRT1 activation in experimental diabetic neuropathy
Elmets et al. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols
JP6509844B2 (ja) 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
Amini et al. Nonsurgical innovations in the treatment of nonmelanoma skin cancer
Bishop et al. Characterisation of ultraviolet-B-induced inflammation as a model of hyperalgesia in the rat
Yarosh et al. Anti-inflammatory activity in skin by biomimetic of Evodia rutaecarpa extract from traditional Chinese medicine
US8029770B2 (en) Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
Alam et al. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA
Nofal et al. Acquired poikiloderma: proposed classification and diagnostic approach
Riffel et al. Systemic administration of vitamins C and E attenuates nociception induced by chronic constriction injury of the sciatic nerve in rats
BR112017004304B1 (pt) uso de pteroestilbeno para prepação de composições tópicas no tratamento de perda de função de barreira na pele induzidas por uv
CN117377475B (zh) 治疗与糖尿病性周围神经病变相关的疼痛
Jin et al. Triclosan induces ROS-dependent cell death and autophagy in A375 melanoma cells
WO2012170467A1 (en) Compositions and methods for restoring the stratum corneum and treating dermatological diseases
Lawrence et al. Mechanism of anthralin inflammation I. Dissociation of response to clobetasol and indomethacin
Kahn et al. A narrative review of nicotinamide adenine dinucleotide (NAD)+ intermediates nicotinamide riboside and nicotinamide mononucleotide for keratinocyte carcinoma risk reduction
US20160067193A1 (en) Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
Kim et al. Chemical stability and in vitro and clinical efficacy of a novel hybrid retinoid derivative, bis-retinamido methylpentane
HK1241310B (en) Topical pterostilbene compositions for use in treating loss of barrier function in skin in burn injurys
Gianfaldoni et al. Vitiligo repigmentation: what’s new
BRPI0719454A2 (pt) "Método de terapia de manutenção do melasma e uso de uma mistura de fluocinolona acetonida, hidroquinona tretinoína"
Swenson et al. Therapeutic effect of NEO400, perillyl alcohol conjugated to linoleic acid, in a mouse model of UV‐induced skin damage
Whitmore et al. The effect of suntan parlor exposure on delayed and contact hypersensitivity
MOURSUND et al. Telangiectasia macularis eruptiva perstans: review of the literature, report of a case and discussion of the etiology and pathology of generalized telangiectasia
BRPI0719466A2 (pt) "método de terapia de manutenção do melasma e uso de uma mistura"

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2790 DE 25-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.